Hostname: page-component-7c8c6479df-r7xzm Total loading time: 0 Render date: 2024-03-19T03:13:57.077Z Has data issue: false hasContentIssue false

An Outbreak of Community-Onset Methicillin-Resistant Staphylococcus aureus Skin Infections in Southwestern Alaska

Published online by Cambridge University Press:  02 January 2015

Henry C. Baggett*
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia
Thomas W. Hennessy
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
Richard Leman
Affiliation:
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia Indian Health Service, Albuquerque, New Mexico
Cindy Hamlin
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
Dana Bruden
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
Alisa Reasonover
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
Patricia Martinez
Affiliation:
Yukon-Kuskokwim Health Corporation, Bethel, Alaska
Jay C. Butler
Affiliation:
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
*
CDC/Arctic Investigations Program, 4055 Tudor Centre Drive, Anchorage, AK 99508

Abstract

Objective:

We investigated a large outbreak of community-onset methicillin-resistant Staphylococcus aureus (MRSA) infections in southwestern Alaska to determine the extent of these infections and whether MRSA isolates were likely community acquired.

Design:

Retrospective cohort study.

Setting:

Rural southwestern Alaska.

Patients:

All patients with a history of culture-confirmed S. aureus infection from March 1, 1999, through August 10, 2000.

Results:

More than 80% of culture-confirmed S. aureus infections were methicillin resistant, and 84% of MRSA infections involved skin or soft tissue; invasive disease was rare. Most (77%) of the patients with MRSA skin infections had communityacquired MRSA (no hospitalization, surgery, dialysis, indwelling line or catheter, or admission to a long-term-care facility in the 12 months before infection). Patients with MRSA skin infections were more likely to have received a prescription for an antimicrobial agent in the 180 days before infection than were patients with methicillin-susceptible S. aureus skin infections.

Conclusions:

Our findings indicate that the epidemiology of MRSA in rural southwestern Alaska has changed and suggest that the emergence of community-onset MRSA in this region was not related to spread of a hospital organism. Treatment guidelines were developed recommending that beta-lactam antimicrobial agents not be used as a first-line therapy for suspected S. aureus infections.

Type
Orginal Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Herold, BC, Immergluck, LC, Maranan, MC, et al.Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593598.CrossRefGoogle ScholarPubMed
2.Gorak, EJ, Yamada, SM, Brown, JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797800.Google Scholar
3.Frank, AL, Marcinak, JF, Mangat, PD, Schreckenberger, PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999;18:9931000.Google Scholar
4.Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. MMWR 1999;48:707710.Google Scholar
5.Adcock, PM, Pastor, P, Medley, F, Murphy, TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis 1998;178:577580.CrossRefGoogle ScholarPubMed
6.Suggs, AH, Maranan, MC, Boyle-Vavra, S, Daum, RS. Methicillin-resistant and borderline methicillin-resistant asymptomatic Staphylococcus aureus colonization in children without identifiable risk factors. Pediatr Infect Dis J 1999;18:410414.Google Scholar
7.Hussain, FM, Boyle-Vavra, S, Bethel, CD, Daum, RS. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000;19:11631166.CrossRefGoogle Scholar
8.Nimmo, GR, Schooneveldt, J, O'Kane, G, McCall, B, Vickery, A. Community acquisition of gentamicin-sensitive methicillin-resistant Staphylococcus aureus in southeast Queensland, Australia. J Clin Microbiol 2000;38:39263931.Google Scholar
9.Layton, MC, Hierholzer, WJ, Patterson, JE. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995;16:1217.Google Scholar
10.Moreno, F, Crisp, C, Jorgensen, JH, Patterson, JE. Methicillin-resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995;21:13081312.Google Scholar
11.Groom, AV, Wolsey, DH, Nami, TS, et al.Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001;286:12011205.CrossRefGoogle Scholar
12.Naimi, TS, LeDell, KH, Boxrud, DJ, et al.Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001;33:990996.Google Scholar
13.Centers for Disease Control. Community-acquired methicillin-resistant Staphylococcus aureus infections: Michigan. MMWR 1981;30:185187.Google Scholar
14.Saravolatz, LD, Pohlod, DJ, Arking, LM. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med 1982;97:325329.CrossRefGoogle ScholarPubMed
15.Berner, BJ. Provision of health care in a frontier setting: an Alaskan perspective. Journal of the American Academy of Nurse Practitioners 1992;4:8994.Google Scholar
16.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999. Standard M2-A7.Google Scholar
17.Unal, S, Hoskins, J, Flokowitsch, JE, Ernie Wu, CY, Preston, DA, Skatrud, PL. Detection of methicillin-resistant Staphylococcus aureus by using the polymerase chain reaction. J Clin Microbiol 1992;30:16851691.Google Scholar
18.Wu, S, de Lencastre, H, Tomasz, A. Genetic organization of the mecA region in methicillin-susceptible and methicillin-resistant strains of Staphylococcus sciuri. J Bacterial 1998;180:236242.Google Scholar
19.Collignon, P, Gosbell, L, Vickery, A, Nimmo, G, Stylianopoulos, XGottlieb, T. Community-acquired methicillin-resistant Staphylococcus aureus in Australia. Lancet 1998;352:145146.Google Scholar
20.Ward, PD, Turner, WH. Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 1980;28:393397.Google Scholar
21.Cribier, B, Prévost, G, Couppie, P, Finck-Barbancon, V, Grosshans, E, Piémont, Y. Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study. Dermatology 1992;185:175180.Google Scholar
22.Prévost, G, Couppie, P, Prévost, P, et al.Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995;42:237245.Google Scholar
23.Lina, G, Piémont, Y, Godail-Gamot, F. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:11281132.CrossRefGoogle ScholarPubMed
24.Thompson, RL, Cabezudo I, Wenzel. Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:309317.Google Scholar
25.Harris, AD, Karchmer, TB, Carmeli, Y, Samore, MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:10551061.Google Scholar
26.State of Alaska. Division of Alcoholism and Drug Abuse Research Reports. Available at www.hss.state.ak.us/dada/research_reports.htm.Google Scholar
27.Markowitz, N, Quinn, EL, Saravolatz, LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390398.Google Scholar
28.de Górgolas, M, Aviles, P, Verdejo, C, Fernández Guerrero, ML. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 1995;39:953957.Google Scholar
29.Jimni, L, Hmouda, H, Letaief, A. Efficacy of trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia. Clin Infect Dis 1994;19:202203.Google Scholar
30.Chambers, HEThe changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178182.Google Scholar